Avalo Therapeutics (AVTX)

• Market cap: $289M
• 1 day: -0.75%
• 5 days: -13.95%
• 1 month: -18.16%
• 3 months: 13.64%
• 6 months: 234.95%
• Year to date: -6.52%
• 1 year: 99.37%
• 5 years: -99.81%
• 10 years: -99.88%
• Sector: Healthcare
• Industry: Biotechnology

About: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 23